Hologic (NASDAQ:HOLX) Updates FY 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.250-4.350 for the period, compared to the consensus estimate of 4.250. The company issued revenue guidance of $4.1 billion-$4.1 billion, compared to the consensus revenue estimate of $4.2 billion. Hologic also updated its Q2 2025 guidance to 1.000-1.030 EPS.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several recent analyst reports. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. William Blair reissued an “outperform” rating on shares of Hologic in a report on Monday, January 13th. Mizuho dropped their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Wolfe Research started coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating for the company. Finally, Royal Bank of Canada raised their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Eight investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.92.

Hologic Price Performance

Hologic stock traded up $1.22 during mid-day trading on Wednesday, hitting $72.80. The stock had a trading volume of 2,779,067 shares, compared to its average volume of 2,293,025. Hologic has a one year low of $68.61 and a one year high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $16.43 billion, a P/E ratio of 21.86, a P/E/G ratio of 2.35 and a beta of 0.98. The firm’s 50 day moving average is $73.05 and its 200 day moving average is $77.98.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. On average, sell-side analysts forecast that Hologic will post 4.28 earnings per share for the current fiscal year.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.88% of the stock is currently owned by corporate insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.